Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL37398 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL1260460 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL16144857 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL2857167 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL14630991 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL1259419 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL15417972 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL15418012 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL1259377 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| Ethyl Acetate SCHEMBL3312144 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | ALDH1A1 2433/4885LMNA 1203/4885HSD17B10 1023/4885 |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | ALDH1A1 3160/4885LMNA 1038/4885HSD17B10 3247/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | ALDH1A1 2433/4885LMNA 1203/4885HSD17B10 1023/4885 |
| US-20120157490-A1 | N-BIARYLAMIDES | GRIN2A, BCHE, ACHE | ALDH1A1 2040/4885LMNA 1312/4885HSD17B10 2479/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | ALDH1A1 2433/4885LMNA 1203/4885HSD17B10 1023/4885 |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | CHRNA7, CHRNA3, CHRNA2 | ALDH1A1 3402/4885LMNA 2324/4885HSD17B10 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.